Wilex AG | Income Statement

Fiscal year is December-November. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
13,317.00
3,597.00
2,284.00
1,362.00
1,900.20
3,667.80
Cost of Goods Sold (COGS) incl. D&A
5,394.00
1,758.00
1,452.00
1,089.00
1,362.90
2,607.10
Gross Income
7,923.00
1,839.00
832.00
273.00
537.30
1,060.70
SG&A Expense
14,061.00
8,532.00
8,987.00
8,015.00
11,871.70
13,438.30
EBIT
5,366.00
6,205.00
7,268.00
6,592.00
11,009.40
11,880
Unusual Expense
4,615.00
87.00
-
-
-
-
Non Operating Income/Expense
5,017.00
716.00
751.00
231.00
256.90
208
Interest Expense
160.00
118.00
1.00
20.00
217.60
-
Pretax Income
5,040.00
5,608.00
6,514.00
6,380.00
10,970.20
11,672
Income Tax
-
93.00
38.00
9.00
-
-
Consolidated Net Income
5,040.00
5,701.00
6,552.00
6,389.00
10,970.20
11,672
Net Income
5,040.00
5,701.00
6,552.00
6,389.00
10,970.20
11,672
Net Income After Extraordinaries
5,040.00
5,701.00
6,552.00
6,389.00
10,970.20
11,672
Net Income Available to Common
5,040.00
5,701.00
6,552.00
6,389.00
10,970.20
11,672
EPS (Basic)
0.60
0.69
0.72
0.51
0.76
0.41
Basic Shares Outstanding
8,279.20
8,279.20
9,180.80
12,488.20
14,372.30
28,209.60
EPS (Diluted)
0.61
0.69
0.71
0.51
0.76
0.41
Diluted Shares Outstanding
8,279.20
8,279.20
9,180.80
12,488.20
14,372.30
28,209.60
EBITDA
3,650.00
5,802.00
6,956.00
6,312.00
10,603.20
11,481
Other Operating Expense
772.00
488.00
887.00
1,150.00
325.00
497.60
Non-Operating Interest Income
84.00
86.00
4.00
1.00
-
-

About Wilex

View Profile
Address
Schriesheimer Strasse 101
Ladenburg Baden Wuerttemberg 68526
Germany
Employees -
Website http://heidelberg-pharma.com
Updated 07/08/2019
Heidelberg Pharma AG engages in the development of diagnostic and therapeutic products for the detection and targeted treatment of various types of cancer. It operates through the following segments: Customer Specific Research (Cx), Diagnostics (Dx), andTherapeutics (Rx). The Customer Specific Research segment includes preclinical and Antibody Drug Conjugate technology services.